TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) — Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) is pleased to announce that it has received both Good Manufacturing Practices and Good Distribution Practices certifications from the national authority in the State of Saxony for the Company’s Ebersbach facility in Germany. Specifically, these certifications are for a 50,000 square foot area within Wayland’s much larger facility located just outside of Dresden, Germany. This marks Wayland’s second facility to receive the EU-GMP certification, the highest standard of pharmaceutical production in the world.
These certifications provide Wayland with the foundation to start selling product into the lucrative German and other developing European markets with drastically shorter lead times and greater margins. The Company will also be able to store bulk product in Germany for sale into the German market, which should serve to eliminate the lengthy process involved in receiving individual export licenses. Selling directly into Germany will allow the Company to capture higher margins for their products as the market remains materially undersupplied.
We have successfully developed a second EU-GMP facility that will increase our presence and penetration of the market for medical cannabis in Germany and throughout the rest of Europe. This milestone makes Wayland the first Canadian licensed producer to have organically achieved an end-to-end EU-GMP distribution and production platform, furthering our competitive advantages at home and abroad.
Ben Ward, CEO of Wayland
About Wayland Group
Wayland is a vertically integrated cultivator and processor of cannabis. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a cannabis cultivation, extraction, formulation, and distribution business under federal licenses from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland and, Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia, and Argentina, in its effort to enhance lives through cannabis.
